Clinical trials: Choroidal Neovascularization
Macular Degeneration, Choroidal Neovascularization
Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging
Clinical trial investigating the role of hyperspectral imaging in the management of patients undergoing standard clinical treatment for naive neovascular choroidal membranes in age-related macular degeneration.
- Trial name
- NCT03105609
- Testing
- Hyperspectral imaging
- Where
- Australia
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Central Retinal Vein Occlusion With Macular Edema
Use of Ziv Aflibercept in Different Retinal Diseases
A prospective interventional case series study was conducted on 20 eyes of 20 patients with active myopic choroidal neovascularisation (CNV) ,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic central…
- Trial name
- NCT04290195
- Testing
- Ziv-Aflibercept 25 MG/ML [Zaltrap]
- Where
- Egypt
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Amin El Sayed Nawar
Uveitis, Diabetic Retinopathy
Biomarkers of Common Eye Diseases
To identify biomarkers of common eye diseases based on single-cell sequencing technologies using PBMC samples. These diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal…
- Conditions
- Uveitis, Diabetic Retinopathy, Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
- Trial name
- NCT04101604
- Testing
- Collection of blood samples
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Wet Macular Degeneration
Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
The purpose of this study is to evaluate the effects and safety of ranibizumab therapy combined with TA versus ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- RANTA (NCT02806752)
- Testing
- Triamcinolone Acetonide, Ranibizumab
- Where
- 7 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Aier School of Ophthalmology, Central South University
Nearsightedness
Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization
The purpose of this study is to gain a better understanding of the retinal vascular changes that occur in response to the optical effect of a myopic defocus daily disposable soft contact lens (MDSL) in a group of healthy young…
- Trial name
- NCT06527274
- Testing
- Experimental: Myopic defocus soft lens design (MDSL), Active Comparator: Single vision soft lens design (SVSL
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Université de Montréal
Myopic Choroidal Neovascularisation
OCTA Changes in Choroidal Neovascularization in High Myopia
To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV..
- Trial name
- NCT06357559
- Testing
- OCTA
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Choroidal Neovascularization, Age Related Macular Degeneration
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
This investigator initiated pilot study is designed to investigate the efficacy and safety of SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to myopia.
- Trial name
- NCT03409250
- Testing
- Ranibizumab, Lucentis
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vista Klinik
Polypoidal Choroidal Vasculopathy
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL (NCT00424710)
- Testing
- ranibizumab intravitreal injection
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hawaii Pacific Health
Angioid Streaks
Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks
The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.
- Trial name
- NCT01015495
- Testing
- ranibizumab
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Choroidal Neovascularization
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
- Trial name
- NCT00403156
- Testing
- Imatinib Mesylate /Ranibizumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Ocular Histoplasmosis Syndrome
Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.
- Trial name
- IVL for OHS (NCT00955630)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Associates of Kentucky
Myopic Choroidal Neovascularization
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
To evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
- Trial name
- NCT00797992
- Testing
- Injection
- Where
- Brazil
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Age Related Macular Degeneration
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
This is an open label study to evaluate 2.0 mg intravitreal aflibercept injection administered in subject who have active choroidal neovascularization due to Age Related Macular Degeneration (AMD).
- Trial name
- NCT01657669
- Testing
- Intravitreal Aflibercept injection
- Where
- 3 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Retina Research Institute, LLC
Choroidal Neovascularization
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
The primary objective: *To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group.
- Trial name
- PVD (NCT01256632)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vision Research Foundation
Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients
Generally, DM is caused by insufficient insulin secretion in the body; however, the other biological mechanisms remain unclear. Long-term illness in patients with DM damages various organs in the body, such as the eyes, kidneys…
- Conditions
- Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation
- Trial name
- NCT06879301
- Testing
- Intravitreal injection of aflibercept 8 mg
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tanta University
Macular Degeneration
A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans
This study is to evaluate the safety, absorption rate and side effects associated with the study drug. Healthy volunteers will be given a single dose of the drug in Part 1.
- Trial name
- NCT01051700
- Testing
- GW786034
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Macular Degeneration, Age-related Macular Degeneration
A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.
This is a two-part study to evaluate the safety, tolerability and pharmacokinetics of single (Part A) and repeat (Part B) eye drop doses of pazopanib in healthy adult and elderly subjects.
- Trial name
- NCT00463320
- Testing
- Pazopanib eye drops and Allergen Refresh Plus eye drops
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Choroidal Neovascularization, Uveitis
Conbercept in Choroidal Neovascularization Secondary to Uveitis
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to uveitis with Conbercept.
- Trial name
- NCT02934841
- Testing
- Conbercept
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chongqing Medical University
Diabetic Retinopathy, Myopia
OCTA Metrics Repeatability and Reproducibility in Different Disorders
Retinal imaging is a corner stone in diagnosis of most retinal disorders. Standard imaging techniques e.g. fluorescein angiography and color fundus photography have a lot of limitations including limited resolution, invasive…
- Conditions
- Diabetic Retinopathy, Myopia, Choroidal Neovascularization, Healthy
- Trial name
- NCT04488887
- Testing
- Optical coherence tomography angiography
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tanta University
Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Choroidal Neovascularization
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.
- Trial name
- NCT04782271
- Testing
- SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.